Celgene Pomalidomide on track for approval in February, says Stifel Nicolaus

theflyonthewall.com

After Celgene updated Phase III data on its pomalidomide cancer drug, Stifel expects the drug to be approved by the FDA in February. The firm continues to expect the drug to generate sales of $594M in 2015 and it maintains a Buy rating on the shares.

Rates

View Comments (0)